Murray A. Raskind, MD

  • 11Articles
  • 47.8KReads
  • 1998–2024Active
  • 26Collaborators
  • 135Citations

About

Murray A. Raskind, MD, is affiliated with the Mental Illness Research, Education, and Clinical Center (MIRECC) at the VA Puget Sound Health Care System in Seattle, Washington, and the Department of Psychiatry and Behavioral Sciences at the University of Washington. Dr. Raskind has contributed to research on topics including posttraumatic stress disorder, dementia, addiction, Alzheimer disease, depression, panic disorder, and psychopharmacology. Publications span from 1998 to 2024 in Psychiatrist.com.

Publications

JCP
Dysregulation of Noradrenergic Activity
Academic Highlights

Dysregulation of Noradrenergic Activity

November 8, 2024

Dysregulation of noradrenergic activity plays a key role in symptom presentation in major depressive disorder, schizophrenia, Alzheimer’s agitation, and PTSD. This article provides an expert panel’s consensus regarding the...
, , , et al
JCP
Article

Doxazosin XL for PTSD

May 25, 2016

One alpha-1 noradrenergic antagonist drug has shown promise in treating PTSD-related sleep disturbances and nightmares, but it has a short half-life. Could the long half-life version of this type...
, , , et al
JCP
Letter to the Editor

Dosing by Side Effect Threshold: Two Cases of Panic Disorder Responsive to Low-Dose Venlafaxine

January 15, 2010

,
JCP
Letter to the Editor

Beneficial Effects of Prazosin for Visual Hallucinations Associated With Chronic Cocaine Abuse

November 15, 2006

, , , et al
JCP
Original Research

Prazosin Reduces Nightmares in Combat Veterans With Posttraumatic Stress Disorder

July 16, 2002

, , , et al
JCP
Letter to the Editor

 Reply to Letter to the Editor "Metrifonate for Alzheimer's Disease Patients"

August 31, 2000

,
JCP
Original Research

The ɑ1-Adrenergic Antagonist Prazosin Ameliorates Combat Trauma Nightmares in Veterans With Posttraumatic Stress Disorder: A Report of 4 Cases

July 31, 2000

, , , et al
JCP
Article

Evaluation and Management of Aggressive Behavior in the Elderly Demented Patient

June 1, 1999

JCP
Original Research

The Effects of Metrifonate on the Cognitive, Behavioral, and Functional Performance of Alzheimer's Disease Patients

May 1, 1999

, , , et al
JCP
Article

Psychopharmacology of Noncognitive Abnormal Behaviors in Alzheimer's Disease

May 1, 1998

JCP
Article

The Clinical Interface of Depression and Dementia

March 1, 1998

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe